Literature DB >> 35596041

Advances in Hydrogel-Based Drug Delivery Systems for Parkinson's Disease.

Thuy Trang Nguyen1, Nguyen Si Bao2,3, Giau Van Vo4,5,6.   

Abstract

Parkinson's disease (PD) is a common central nervous system disorder (CNS) characterized by cell loss in the substantia nigra. Severe loss of dopaminergic neurons and Lewy body formation with α-synuclein inclusions are the main neuropathological features of PD. There's currently no cure for PD, but treatments are available to help relieve the symptoms and maintain quality of life. However, the variety of clinically available therapeutic molecules is mainly limited to treating symptoms rather than halting or reversing disease progression via medical interventions. As an emerging drug carrier, hydrogels loaded with therapeutic agents and cells are attracting attention as an alternative and potentially more effective approach to managing PD. The current work highlights applications of hydrogel-based biomaterials in cell culture and disease modeling as carriers for cells, medicines, and proteins as PD therapeutic models.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Biomaterials; Drug carrier; Hydrogels; Parkinson’s disease; Treatment

Mesh:

Substances:

Year:  2022        PMID: 35596041     DOI: 10.1007/s11064-022-03617-w

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   4.414


  42 in total

1.  A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa.

Authors:  O Rascol; D J Brooks; A D Korczyn; P P De Deyn; C E Clarke; A E Lang
Journal:  N Engl J Med       Date:  2000-05-18       Impact factor: 91.245

2.  Combinational Hydrogel and Xerogel Actuators Showing NIR Manipulating Complex Actions.

Authors:  Shurui Yang; Yuancheng Zhang; Chao Zhang; Tao Wang; Weixiang Sun; Zhen Tong
Journal:  Macromol Rapid Commun       Date:  2019-07-11       Impact factor: 5.734

Review 3.  Advances in developing therapeutic strategies for Alzheimer's disease.

Authors:  Thuy Trang Nguyen; Thuy Dung Nguyen; Thi Kim Oanh Nguyen; Tuong Kha Vo; Van Giau Vo
Journal:  Biomed Pharmacother       Date:  2021-04-26       Impact factor: 6.529

Review 4.  Lipid-Based Nanocarriers via Nose-to-Brain Pathway for Central Nervous System Disorders.

Authors:  Thuy Trang Nguyen; Thi Thuy Dung Nguyen; Nguyen-Minh-An Tran; Giau Van Vo
Journal:  Neurochem Res       Date:  2021-11-20       Impact factor: 3.996

Review 5.  Levodopa in the treatment of Parkinson's disease: current status and new developments.

Authors:  David Salat; Eduardo Tolosa
Journal:  J Parkinsons Dis       Date:  2013-01-01       Impact factor: 5.568

Review 6.  Nanotechnology-based drug delivery for central nervous system disorders.

Authors:  Thuy Trang Nguyen; Thi Thuy Dung Nguyen; Tuong Kha Vo; Nguyen-Minh-An Tran; Minh Kim Nguyen; Toi Van Vo; Giau Van Vo
Journal:  Biomed Pharmacother       Date:  2021-08-31       Impact factor: 6.529

Review 7.  Levodopa in the treatment of Parkinson's disease: an old drug still going strong.

Authors:  Werner Poewe; Angelo Antonini; Jan Cm Zijlmans; Pierre R Burkhard; François Vingerhoets
Journal:  Clin Interv Aging       Date:  2010-09-07       Impact factor: 4.458

Review 8.  The Emerging Evidence of the Parkinson Pandemic.

Authors:  E Ray Dorsey; Todd Sherer; Michael S Okun; Bastiaan R Bloem
Journal:  J Parkinsons Dis       Date:  2018       Impact factor: 5.568

9.  Optimizing levodopa therapy for Parkinson's disease with levodopa/carbidopa/entacapone: implications from a clinical and patient perspective.

Authors:  David J Brooks
Journal:  Neuropsychiatr Dis Treat       Date:  2008-02       Impact factor: 2.570

Review 10.  Hydrogels for neuroprotection and functional rewiring: a new era for brain engineering.

Authors:  Rocío Fernandez-Serra; Rebeca Gallego; Paloma Lozano; Daniel González-Nieto
Journal:  Neural Regen Res       Date:  2020-05       Impact factor: 5.135

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.